Targacept, Inc.
Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia
Published in Mental Health Business Week, January 2nd, 2010
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia. TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, or NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as PentadTM.
"We believe that currently available treatment options do not adequately address the dramatic impact schizophrenia has on cognition for millions of patients. Medications capable of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
More Articles from Mental Health Business Week
- Alexza Pharmaceuticals, Inc.
Alexza Announces Submission of AZ-004 Staccato Loxapine NDA - Amazon.com, Inc.
Blind and Vision-Impaired Readers to Benefit from New Kindle Features in 2010 - Autism Spectrum Therapies
Autism Spectrum Therapies Offers Tips for Parents on Selecting the Best Autism Service Provider for Their Child - Bipolar Disorder
First-Of-Its-Kind Anthology Voices of BiPolar Disorder Available - Bullying
Middle Schoolers Identify Violent Content in Youth-Targeted Entertainment as a Strong Influence in Causing Youth Violence - California Office of Traffic Safety
California Law Enforcement Announces 2010 as 'The Year of the Checkpoint' - More from this issue of Mental Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
